NEW YORK, Oct. 12, 2013 /PRNewswire/ --
Atossa Genetics, Inc. Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty by the board of directors of Atossa Genetics, Inc. ("Atossa" or the "Company"). On October 4, 2013, Atossa announced it had commenced the voluntary recall of the ForeCYTE Breast Health Test Mammary Aspiration Specimen Cytology Test. In February 2013, the Company received a warning letter from the FDA. The FDA raised concerns about (1) the current instructions for use ("IFU"); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid specimen collection process identified in the current IFU. Atossa will remove existing product from the market until FDA's concerns are addressed.
For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: firstname.lastname@example.org.
Francesca's Holdings Corporation Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the Southern District of New York, alleging that Francesca's Holdings Corporation ("FRAN") issued false and misleading statements to investors between March 20, 2013 and September 3, 2013, inclusive (the "Class Period") by failing to disclose that: (i) spring and summer weather and a competitive back-to-school retail environment weighed on same-store sales growth; and (ii) same-store sales were declining.For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: email@example.com. Greenway Medical Technologies, Inc. Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Greenway Medical Technologies, Inc. ("GWAY") to Vista Equity Partners in a transaction valued at approximately $644 million or $20.35 per share in cash. Lifshitz Law Firm's investigation is focused on whether the proposed deal provides adequate value to GWAY's shareholders.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts